title: CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab.
abstract: OBJECTIVE
  The purpose of this article is to provide a practical review of newly established morphologic tumor response criteria for hepatic colorectal metastasis treated with bevacizumab-containing chemotherapy and a description of the patterns of early recurrence. We also discuss the respective value of these criteria and the Response Evaluation Criteria in Solid Tumors (RECIST).
  
  
  CONCLUSIONS
  RECIST alone are not sufficient to assess response after bevacizumab-containing chemotherapy for hepatic colorectal metastasis. The combined use of RECIST and morphologic criteria is mandatory for optimal evaluation in this population.
authors: Department of Diagnostic Radiology, The University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA.
authors: Piyaporn
authors: P
authors: Boonsirikamchai
authors: Mohamed Aly
authors: MA
authors: Asran
authors: Dipen M
authors: DM
authors: Maru
authors: Jean-Nicolas
authors: JN
authors: Vauthey
authors: Harmeet
authors: H
authors: Kaur
authors: Scott
authors: S
authors: Kopetz
authors: Evelyne M
authors: EM
authors: Loyer
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000473:pathology*; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000556:secondary*; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging*; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab